학술논문
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
Document Type
Article
Author
Badar, T.; Szabo, A.; Khan, M.A.; Atallah, E.; Dinner, S.; Burkart, M.; Liedtke, M.; Yurkiewicz, I.R.; Kuo, E.; Shallis, R.M.; Podoltsev, N.; Balasubramanian, S.; Yang, J.; Hefazi, M.; Litzow, M.R.; Patel, A.; Curran, E.; Wang, A.; Arslan, S.; Aldoss, I.; Siebenaller, C.; Advani, A.S.; Mattison, R.J.; Wadleigh, M.
Source
In: Cancer . (Cancer, 1 April 2021, 127(7):1039-1048)
Subject
Language
English
ISSN
10970142
0008543X
0008543X